Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07726771

Evaluation of the Ileo-anal Pouch in FAP (ENDOPOL)

Evaluation of the Ileo-anal Pouch in FAP (ENDOPOL) — Recruiting • Non-phase study • Oncology • NCT07726771.

📅 24 Jul 2026 ⏱ 5 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07726771
Sponsor
London North West Healthcare NHS Trust
Start
2026-07-09
ClinicaliQ Trial Snapshot
  • Evaluation of the Ileo-anal Pouch in FAP (ENDOPOL) — Recruiting • Non-phase study • Oncology • NCT07726771.
  • What is being tested: This RCT compares dye-based chromoendoscopy versus virtual chromoendoscopy (NBI/BLI technology) for detecting adenomas during surveillance pouchoscopy in FAP patients with ileal pouch-anal anastomosis (IPAA).
  • Patient eligibility overview: The trial includes adults with FAP who have undergone IPAA surgery and require routine pouch surveillance as part of their standard cancer prevention care.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This international, multi-centre randomised controlled trial will compare dye-based chromoendoscopy with virtual chromoendoscopy, using NBI/BLI, for adenoma detection during routine surveillance pouchoscopy in adults with familial adenomatous polyposis (FAP) and an ileal pouch-anal anastomosis (IPAA). The estimated study duration is 2 years. Participants will undergo their usual scheduled pouchoscopy, performed by endoscopists experienced in FAP. Before the procedure, they will be randomised 1:1 to dye-based or virtual chromoendoscopy. Adenomas requiring endoscopic treatment will be removed during the same procedure according to standard practice. To our knowledge, no previous study has…

Eligibility Snapshot
  • : ALL of the following: 1. Diagnosis of FAP i.e., at least one of following: * Genetic diagnosis: proven APC germline mutation OR * Clinical diagnosis: >100 colorectal adenomas in combination with a positive family history of FAP 2. Have an ileal-pouch anal anastomosis (IPAA), either after primary proctocolectomy or secondary proctectomy after initial colectomy and ileorectal or ileosigmoidal anastomosis (IRA/ISA) 3. Age ≥ 18 years

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Guideline
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Oncology · 26 Aug 2026
Test for MSI-H/dMMR before treatment: All patients with advanced or recurrent endometrial cancer should undergo microsatellite instability or mismatch repair deficiency testing…
View guideline →
Guideline
Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)
Oncology · 20 Aug 2026
This NICE evaluation was terminated, meaning lisocabtagene maraleucel is not currently recommended for routine NHS use in relapsed or refractory follicular lymphoma—do…
View guideline →
Clinical Brief
Very hot drinks may damage the food pipe and increase cancer risk
Oncology · BBC Health · 09 Sep 2026
The International Agency for Research on Cancer (IARC) has classified drinking "very hot" beverages (>65°C) as a probable carcinogen (Group 2A), associated…
View brief →